C-mo Medical Solutions is revolutionizing cough assessment and disease management with the power of digital health! With the recent funding from Novalis Biotech, this pioneering start-up is unlocking the potential of cough monitoring and paving the way for a new era of healthcare.
C-mo Medical Solutions has announced an exciting expansion to its seed investment round, now totaling a whopping €4.8 million. The round has been bolstered by the addition of Novalis Biotech, joining the existing list of investors that include Boehringer Ingelheim Venture Fund, Portugal Ventures, and High-Tech Gründerfonds (HTGF). This new injection of funding will help C-mo Medical Solutions continue to innovate and create cutting-edge medical solutions.
At C-mo Medical Solutions, we are taking on the challenge of improving how chronic cough is assessed and managed. We understand how this symptom affects the lives of more than 700 million adults worldwide and want to provide the necessary tools to help them live better lives. Our CEO, Diogo Tecelão, puts it best: “Cough can tell us so much about a patient’s health. It’s time to make use of this valuable information and make a real difference in people’s lives.” Our mission is to do just that!
C-mo is revolutionizing cough assessment with its cutting-edge product suite! According to Diogo Tecelão, C-mo’s technology is able to detect the subtle nuances of a patient’s cough and turn them into valuable insights that can be used to accelerate diagnosis, optimize treatment, manage diseases, and support pharmaceutical research. With C-mo, the potential of cough assessment is now unlocked.
Novalis Biotech’s Fund Manager, Kjell Mortier, is thrilled to be part of the investor consortium and support C-mo. He is in awe of the C-mo team’s dedication and the way they have translated a clinically relevant symptom, such as cough, into an objective, measurable marker. Mortier believes this technology will help patients gain access to the right treatment and better assess and treat underlying conditions.
We are delighted to have Novalis Biotech join us as an investor, as their expertise in healthcare will be a great asset to our company! This additional capital injection will enable us to further develop our cough assessment technology, enabling us to unlock its full potential and explore its various applications. Diogo Tecelão, CEO of our company, is thrilled with this development, and we look forward to seeing what the future holds!
About C-mo Medical Solutions
C-mo Medical Solutions is revolutionizing the way we diagnose and manage medical conditions related to coughing. This forward-thinking Digital Health start-up has earned numerous awards for their innovative approach and has a mission to unleash the full clinical potential of cough assessment and tackle the unmet medical needs associated with chronic cough.
About Novalis Biotech
Novalis Biotech (Ghent, Belgium) is an innovative venture capital investor revolutionizing healthcare with its digitalization strategies. Specializing in capital-light “enabling technologies” such as bioinformatics, AI, genomics, personalized medicine, research and manufacturing tools, and diagnostics, Novalis Biotech has the potential to change how healthcare is approached and delivered.